Cambridge Healthtech Institute’s Inaugural

Peptides & Emerging Drug Conjugates

Design and Delivery for Developing Novel Peptide, Antibody and Radioligand Modalities

March 18-19, 2026

Cambridge Healthtech Institute’s inaugural conference on Peptides & Emerging Drug Conjugates brings together chemists, biologists, and formulation experts looking to design and deliver targeted therapies to overcome existing limitations. Utilizing AI/ML predictions, innovative conjugate and linker chemistries, and novel formulation and delivery techniques, these drugs and delivery vehicles are designed to be tissue-specific, cell-permeable, orally bioavailable for tackling challenging disease indications. The talks and discussions will provide insights on how to improve stability, bioavailability and deliverability of these modalities while reducing immunogenicity and safety concerns.

Coverage will include, but is not limited to:

Designing and delivering diverse peptides, antibody, and radioligand conjugates
Antibody and peptide conjugation with small molecules, degraders, oligos, radioligands, lipids, sugars, antigens
New tools and methods for optimizing biodistribution (linker chemistries, internalization mechanisms)
AI/ML-based prediction and analysis for optimizing binding, membrane permeability, and cell targeting
New formulations and delivery vehicles for targeted cell permeability and tissue-specificity
Case studies highlighting novel modalities for obesity, metabolism, oncology, immunology and more

The deadline for priority consideration is September 5, 2025.

Submit a Proposal »

All proposals are subject to review by session chairpersons and/or the Scientific Advisory Committee to ensure the overall quality of the conference program. Additionally, as per Cambridge Healthtech Institute’s policy, a select number of vendors and consultants who provide products and services will be offered opportunities for podium presentation slots based on a variety of Corporate Sponsorships.

Opportunities for Participation: